Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed Feb 12, 2021 · 10-Q · 43 days after period end · 0001493152-21-003609
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Net Income | -$403.64K | -$1.87M | -$1.45M | -$2.20M |
| EPS Diluted | -$0.45 | -$1,250.78 | -$41.33 | -$0.20 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Feb 12, 2021 · 43 d after period end
